What is the current valuation of the Human Rabies Vaccine Market as of 2024?

The market was valued at 0.6245 USD Billion in 2024. Read More

What is the projected market valuation for the Human Rabies Vaccine Market in 2035?

The market is projected to reach 1.312 USD Billion by 2035. Read More

What is the expected CAGR for the market during the forecast period 2025 - 2035?

The expected CAGR for the market during the forecast period is 6.98%. Read More

Which companies are considered key players in the Human Rabies Vaccine Market?

Key players include Sanofi, Bharat Biotech, Merck & Co., GlaxoSmithKline, Serum Institute of India, Pfizer, Haffkine Bio-Pharmaceutical Corporation, and Zydus Cadila. Read More

What are the different types of vaccines available in the Human Rabies Vaccine Market?

The market includes Killed Virus Vaccine, Modified Live Virus Vaccine, and Recombinant Vaccine. Read More

How does the market segment for Route of Administration break down?

The Route of Administration segment includes Intramuscular Injection, Intradermal Injection, and Subcutaneous Injection. Read More

What are the immunoglobulin types available in the Human Rabies Vaccine Market?

The market features Human Rabies Immunoglobulin (HRIG) and Equine Rabies Immunoglobulin (ERIG). Read More

What applications are covered in the market?

Applications include Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis. Read More

What dosage forms are available in the Human Rabies Vaccine Market?

The market offers Vials and Pre-Filled Syringes as dosage forms. Read More

What was the valuation of the Killed Virus Vaccine segment in 2024?

The Killed Virus Vaccine segment was valued at 0.3747 USD Billion in 2024. Read More

Human Rabies Vaccine Market

ID: MRFR/Pharma/28928-HCR

100 Pages

Rahul Gotadki

Last Updated: April 22, 2026

Human Rabies Vaccine Market Research Report By Vaccine Type (Killed Virus Vaccine, Modified Live Virus Vaccine, Recombinant Vaccine), By Route of Administration (Intramuscular Injection, Intradermal Injection, Subcutaneous Injection), By Immunoglobulins (Human Rabies Immunoglobulin (HRIG), Equine Rabies Immunoglobulin (ERIG)), By Application (Pre-Exposure Prophylaxis, Post-Exposure Prophylaxis), By Dosage Form (Vials, Pre-Filled Syringes) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Type (USD Billion) | |
  1. 4.1.1 Killed Virus Vaccine | |
  2. 4.1.2 Modified Live Virus Vaccine | |
  3. 4.1.3 Recombinant Vaccine |
2. 4.2 Healthcare, BY Route of Administration (USD Billion) | |
  1. 4.2.1 Intramuscular Injection | |
  2. 4.2.2 Intradermal Injection | |
  3. 4.2.3 Subcutaneous Injection |
3. 4.3 Healthcare, BY Immunoglobulins (USD Billion) | |
  1. 4.3.1 Human Rabies Immunoglobulin (HRIG) | |
  2. 4.3.2 Equine Rabies Immunoglobulin (ERIG) |
4. 4.4 Healthcare, BY Application (USD Billion) | |
  1. 4.4.1 Pre-Exposure Prophylaxis | |
  2. 4.4.2 Post-Exposure Prophylaxis |
5. 4.5 Healthcare, BY Dosage Form (USD Billion) | |
  1. 4.5.1 Vials | |
  2. 4.5.2 Pre-Filled Syringes |
6. 4.6 Healthcare, BY Region (USD Billion) | |
  1. 4.6.1 North America | | |
    1. 4.6.1.1 US | | |
    2. 4.6.1.2 Canada | |
  2. 4.6.2 Europe | | |
    1. 4.6.2.1 Germany | | |
    2. 4.6.2.2 UK | | |
    3. 4.6.2.3 France | | |
    4. 4.6.2.4 Russia | | |
    5. 4.6.2.5 Italy | | |
    6. 4.6.2.6 Spain | | |
    7. 4.6.2.7 Rest of Europe | |
  3. 4.6.3 APAC | | |
    1. 4.6.3.1 China | | |
    2. 4.6.3.2 India | | |
    3. 4.6.3.3 Japan | | |
    4. 4.6.3.4 South Korea | | |
    5. 4.6.3.5 Malaysia | | |
    6. 4.6.3.6 Thailand | | |
    7. 4.6.3.7 Indonesia | | |
    8. 4.6.3.8 Rest of APAC | |
  4. 4.6.4 South America | | |
    1. 4.6.4.1 Brazil | | |
    2. 4.6.4.2 Mexico | | |
    3. 4.6.4.3 Argentina | | |
    4. 4.6.4.4 Rest of South America | |
  5. 4.6.5 MEA | | |
    1. 4.6.5.1 GCC Countries | | |
    2. 4.6.5.2 South Africa | | |
    3. 4.6.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Sanofi (FR) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Bharat Biotech (IN) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Merck & Co. (US) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 GlaxoSmithKline (GB) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Serum Institute of India (IN) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Pfizer (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Haffkine Bio-Pharmaceutical Corporation (IN) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Zydus Cadila (IN) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY TYPE |
7. 6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
8. 6.5 US MARKET ANALYSIS BY IMMUNOGLOBULINS |
9. 6.6 US MARKET ANALYSIS BY APPLICATION |
10. 6.7 US MARKET ANALYSIS BY DOSAGE FORM |
11. 6.8 CANADA MARKET ANALYSIS BY TYPE |
12. 6.9 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
13. 6.10 CANADA MARKET ANALYSIS BY IMMUNOGLOBULINS |
14. 6.11 CANADA MARKET ANALYSIS BY APPLICATION |
15. 6.12 CANADA MARKET ANALYSIS BY DOSAGE FORM |
16. 6.13 EUROPE MARKET ANALYSIS |
17. 6.14 GERMANY MARKET ANALYSIS BY TYPE |
18. 6.15 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
19. 6.16 GERMANY MARKET ANALYSIS BY IMMUNOGLOBULINS |
20. 6.17 GERMANY MARKET ANALYSIS BY APPLICATION |
21. 6.18 GERMANY MARKET ANALYSIS BY DOSAGE FORM |
22. 6.19 UK MARKET ANALYSIS BY TYPE |
23. 6.20 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
24. 6.21 UK MARKET ANALYSIS BY IMMUNOGLOBULINS |
25. 6.22 UK MARKET ANALYSIS BY APPLICATION |
26. 6.23 UK MARKET ANALYSIS BY DOSAGE FORM |
27. 6.24 FRANCE MARKET ANALYSIS BY TYPE |
28. 6.25 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
29. 6.26 FRANCE MARKET ANALYSIS BY IMMUNOGLOBULINS |
30. 6.27 FRANCE MARKET ANALYSIS BY APPLICATION |
31. 6.28 FRANCE MARKET ANALYSIS BY DOSAGE FORM |
32. 6.29 RUSSIA MARKET ANALYSIS BY TYPE |
33. 6.30 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
34. 6.31 RUSSIA MARKET ANALYSIS BY IMMUNOGLOBULINS |
35. 6.32 RUSSIA MARKET ANALYSIS BY APPLICATION |
36. 6.33 RUSSIA MARKET ANALYSIS BY DOSAGE FORM |
37. 6.34 ITALY MARKET ANALYSIS BY TYPE |
38. 6.35 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
39. 6.36 ITALY MARKET ANALYSIS BY IMMUNOGLOBULINS |
40. 6.37 ITALY MARKET ANALYSIS BY APPLICATION |
41. 6.38 ITALY MARKET ANALYSIS BY DOSAGE FORM |
42. 6.39 SPAIN MARKET ANALYSIS BY TYPE |
43. 6.40 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
44. 6.41 SPAIN MARKET ANALYSIS BY IMMUNOGLOBULINS |
45. 6.42 SPAIN MARKET ANALYSIS BY APPLICATION |
46. 6.43 SPAIN MARKET ANALYSIS BY DOSAGE FORM |
47. 6.44 REST OF EUROPE MARKET ANALYSIS BY TYPE |
48. 6.45 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
49. 6.46 REST OF EUROPE MARKET ANALYSIS BY IMMUNOGLOBULINS |
50. 6.47 REST OF EUROPE MARKET ANALYSIS BY APPLICATION |
51. 6.48 REST OF EUROPE MARKET ANALYSIS BY DOSAGE FORM |
52. 6.49 APAC MARKET ANALYSIS |
53. 6.50 CHINA MARKET ANALYSIS BY TYPE |
54. 6.51 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
55. 6.52 CHINA MARKET ANALYSIS BY IMMUNOGLOBULINS |
56. 6.53 CHINA MARKET ANALYSIS BY APPLICATION |
57. 6.54 CHINA MARKET ANALYSIS BY DOSAGE FORM |
58. 6.55 INDIA MARKET ANALYSIS BY TYPE |
59. 6.56 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
60. 6.57 INDIA MARKET ANALYSIS BY IMMUNOGLOBULINS |
61. 6.58 INDIA MARKET ANALYSIS BY APPLICATION |
62. 6.59 INDIA MARKET ANALYSIS BY DOSAGE FORM |
63. 6.60 JAPAN MARKET ANALYSIS BY TYPE |
64. 6.61 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
65. 6.62 JAPAN MARKET ANALYSIS BY IMMUNOGLOBULINS |
66. 6.63 JAPAN MARKET ANALYSIS BY APPLICATION |
67. 6.64 JAPAN MARKET ANALYSIS BY DOSAGE FORM |
68. 6.65 SOUTH KOREA MARKET ANALYSIS BY TYPE |
69. 6.66 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
70. 6.67 SOUTH KOREA MARKET ANALYSIS BY IMMUNOGLOBULINS |
71. 6.68 SOUTH KOREA MARKET ANALYSIS BY APPLICATION |
72. 6.69 SOUTH KOREA MARKET ANALYSIS BY DOSAGE FORM |
73. 6.70 MALAYSIA MARKET ANALYSIS BY TYPE |
74. 6.71 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
75. 6.72 MALAYSIA MARKET ANALYSIS BY IMMUNOGLOBULINS |
76. 6.73 MALAYSIA MARKET ANALYSIS BY APPLICATION |
77. 6.74 MALAYSIA MARKET ANALYSIS BY DOSAGE FORM |
78. 6.75 THAILAND MARKET ANALYSIS BY TYPE |
79. 6.76 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
80. 6.77 THAILAND MARKET ANALYSIS BY IMMUNOGLOBULINS |
81. 6.78 THAILAND MARKET ANALYSIS BY APPLICATION |
82. 6.79 THAILAND MARKET ANALYSIS BY DOSAGE FORM |
83. 6.80 INDONESIA MARKET ANALYSIS BY TYPE |
84. 6.81 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
85. 6.82 INDONESIA MARKET ANALYSIS BY IMMUNOGLOBULINS |
86. 6.83 INDONESIA MARKET ANALYSIS BY APPLICATION |
87. 6.84 INDONESIA MARKET ANALYSIS BY DOSAGE FORM |
88. 6.85 REST OF APAC MARKET ANALYSIS BY TYPE |
89. 6.86 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
90. 6.87 REST OF APAC MARKET ANALYSIS BY IMMUNOGLOBULINS |
91. 6.88 REST OF APAC MARKET ANALYSIS BY APPLICATION |
92. 6.89 REST OF APAC MARKET ANALYSIS BY DOSAGE FORM |
93. 6.90 SOUTH AMERICA MARKET ANALYSIS |
94. 6.91 BRAZIL MARKET ANALYSIS BY TYPE |
95. 6.92 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
96. 6.93 BRAZIL MARKET ANALYSIS BY IMMUNOGLOBULINS |
97. 6.94 BRAZIL MARKET ANALYSIS BY APPLICATION |
98. 6.95 BRAZIL MARKET ANALYSIS BY DOSAGE FORM |
99. 6.96 MEXICO MARKET ANALYSIS BY TYPE |
100. 6.97 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
101. 6.98 MEXICO MARKET ANALYSIS BY IMMUNOGLOBULINS |
102. 6.99 MEXICO MARKET ANALYSIS BY APPLICATION |
103. 6.100 MEXICO MARKET ANALYSIS BY DOSAGE FORM |
104. 6.101 ARGENTINA MARKET ANALYSIS BY TYPE |
105. 6.102 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
106. 6.103 ARGENTINA MARKET ANALYSIS BY IMMUNOGLOBULINS |
107. 6.104 ARGENTINA MARKET ANALYSIS BY APPLICATION |
108. 6.105 ARGENTINA MARKET ANALYSIS BY DOSAGE FORM |
109. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE |
110. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
111. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY IMMUNOGLOBULINS |
112. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION |
113. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY DOSAGE FORM |
114. 6.111 MEA MARKET ANALYSIS |
115. 6.112 GCC COUNTRIES MARKET ANALYSIS BY TYPE |
116. 6.113 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
117. 6.114 GCC COUNTRIES MARKET ANALYSIS BY IMMUNOGLOBULINS |
118. 6.115 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION |
119. 6.116 GCC COUNTRIES MARKET ANALYSIS BY DOSAGE FORM |
120. 6.117 SOUTH AFRICA MARKET ANALYSIS BY TYPE |
121. 6.118 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
122. 6.119 SOUTH AFRICA MARKET ANALYSIS BY IMMUNOGLOBULINS |
123. 6.120 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION |
124. 6.121 SOUTH AFRICA MARKET ANALYSIS BY DOSAGE FORM |
125. 6.122 REST OF MEA MARKET ANALYSIS BY TYPE |
126. 6.123 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
127. 6.124 REST OF MEA MARKET ANALYSIS BY IMMUNOGLOBULINS |
128. 6.125 REST OF MEA MARKET ANALYSIS BY APPLICATION |
129. 6.126 REST OF MEA MARKET ANALYSIS BY DOSAGE FORM |
130. 6.127 KEY BUYING CRITERIA OF HEALTHCARE |
131. 6.128 RESEARCH PROCESS OF MRFR |
132. 6.129 DRO ANALYSIS OF HEALTHCARE |
133. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
134. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
135. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE |
136. 6.133 HEALTHCARE, BY TYPE, 2024 (% SHARE) |
137. 6.134 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion) |
138. 6.135 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE) |
139. 6.136 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion) |
140. 6.137 HEALTHCARE, BY IMMUNOGLOBULINS, 2024 (% SHARE) |
141. 6.138 HEALTHCARE, BY IMMUNOGLOBULINS, 2024 TO 2035 (USD Billion) |
142. 6.139 HEALTHCARE, BY APPLICATION, 2024 (% SHARE) |
143. 6.140 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion) |
144. 6.141 HEALTHCARE, BY DOSAGE FORM, 2024 (% SHARE) |
145. 6.142 HEALTHCARE, BY DOSAGE FORM, 2024 TO 2035 (USD Billion) |
146. 6.143 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
147. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
148. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY IMMUNOGLOBULINS, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY APPLICATION, 2025-2035 (USD Billion) | |
  5. 7.2.5 BY DOSAGE FORM, 2025-2035 (USD Billion) |
149. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY IMMUNOGLOBULINS, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY APPLICATION, 2025-2035 (USD Billion) | |
  5. 7.3.5 BY DOSAGE FORM, 2025-2035 (USD Billion) |
150. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY IMMUNOGLOBULINS, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY APPLICATION, 2025-2035 (USD Billion) | |
  5. 7.4.5 BY DOSAGE FORM, 2025-2035 (USD Billion) |
151. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY IMMUNOGLOBULINS, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY APPLICATION, 2025-2035 (USD Billion) | |
  5. 7.5.5 BY DOSAGE FORM, 2025-2035 (USD Billion) |
152. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY IMMUNOGLOBULINS, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY APPLICATION, 2025-2035 (USD Billion) | |
  5. 7.6.5 BY DOSAGE FORM, 2025-2035 (USD Billion) |
153. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY IMMUNOGLOBULINS, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY APPLICATION, 2025-2035 (USD Billion) | |
  5. 7.7.5 BY DOSAGE FORM, 2025-2035 (USD Billion) |
154. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY IMMUNOGLOBULINS, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY APPLICATION, 2025-2035 (USD Billion) | |
  5. 7.8.5 BY DOSAGE FORM, 2025-2035 (USD Billion) |
155. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY IMMUNOGLOBULINS, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY APPLICATION, 2025-2035 (USD Billion) | |
  5. 7.9.5 BY DOSAGE FORM, 2025-2035 (USD Billion) |
156. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY IMMUNOGLOBULINS, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY APPLICATION, 2025-2035 (USD Billion) | |
  5. 7.10.5 BY DOSAGE FORM, 2025-2035 (USD Billion) |
157. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY IMMUNOGLOBULINS, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY APPLICATION, 2025-2035 (USD Billion) | |
  5. 7.11.5 BY DOSAGE FORM, 2025-2035 (USD Billion) |
158. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY IMMUNOGLOBULINS, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY APPLICATION, 2025-2035 (USD Billion) | |
  5. 7.12.5 BY DOSAGE FORM, 2025-2035 (USD Billion) |
159. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY IMMUNOGLOBULINS, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY APPLICATION, 2025-2035 (USD Billion) | |
  5. 7.13.5 BY DOSAGE FORM, 2025-2035 (USD Billion) |
160. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY IMMUNOGLOBULINS, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY APPLICATION, 2025-2035 (USD Billion) | |
  5. 7.14.5 BY DOSAGE FORM, 2025-2035 (USD Billion) |
161. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY IMMUNOGLOBULINS, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY APPLICATION, 2025-2035 (USD Billion) | |
  5. 7.15.5 BY DOSAGE FORM, 2025-2035 (USD Billion) |
162. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY IMMUNOGLOBULINS, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY APPLICATION, 2025-2035 (USD Billion) | |
  5. 7.16.5 BY DOSAGE FORM, 2025-2035 (USD Billion) |
163. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY IMMUNOGLOBULINS, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY APPLICATION, 2025-2035 (USD Billion) | |
  5. 7.17.5 BY DOSAGE FORM, 2025-2035 (USD Billion) |
164. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY IMMUNOGLOBULINS, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY APPLICATION, 2025-2035 (USD Billion) | |
  5. 7.18.5 BY DOSAGE FORM, 2025-2035 (USD Billion) |
165. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY IMMUNOGLOBULINS, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY APPLICATION, 2025-2035 (USD Billion) | |
  5. 7.19.5 BY DOSAGE FORM, 2025-2035 (USD Billion) |
166. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY IMMUNOGLOBULINS, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY APPLICATION, 2025-2035 (USD Billion) | |
  5. 7.20.5 BY DOSAGE FORM, 2025-2035 (USD Billion) |
167. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY IMMUNOGLOBULINS, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY APPLICATION, 2025-2035 (USD Billion) | |
  5. 7.21.5 BY DOSAGE FORM, 2025-2035 (USD Billion) |
168. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY IMMUNOGLOBULINS, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY APPLICATION, 2025-2035 (USD Billion) | |
  5. 7.22.5 BY DOSAGE FORM, 2025-2035 (USD Billion) |
169. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY IMMUNOGLOBULINS, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY APPLICATION, 2025-2035 (USD Billion) | |
  5. 7.23.5 BY DOSAGE FORM, 2025-2035 (USD Billion) |
170. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY IMMUNOGLOBULINS, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY APPLICATION, 2025-2035 (USD Billion) | |
  5. 7.24.5 BY DOSAGE FORM, 2025-2035 (USD Billion) |
171. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY IMMUNOGLOBULINS, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY APPLICATION, 2025-2035 (USD Billion) | |
  5. 7.25.5 BY DOSAGE FORM, 2025-2035 (USD Billion) |
172. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY IMMUNOGLOBULINS, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY APPLICATION, 2025-2035 (USD Billion) | |
  5. 7.26.5 BY DOSAGE FORM, 2025-2035 (USD Billion) |
173. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY IMMUNOGLOBULINS, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY APPLICATION, 2025-2035 (USD Billion) | |
  5. 7.27.5 BY DOSAGE FORM, 2025-2035 (USD Billion) |
174. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY IMMUNOGLOBULINS, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY APPLICATION, 2025-2035 (USD Billion) | |
  5. 7.28.5 BY DOSAGE FORM, 2025-2035 (USD Billion) |
175. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY IMMUNOGLOBULINS, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY APPLICATION, 2025-2035 (USD Billion) | |
  5. 7.29.5 BY DOSAGE FORM, 2025-2035 (USD Billion) |
176. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY IMMUNOGLOBULINS, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY APPLICATION, 2025-2035 (USD Billion) | |
  5. 7.30.5 BY DOSAGE FORM, 2025-2035 (USD Billion) |
177. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
178. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Type (USD Billion, 2025-2035)

Killed Virus Vaccine
Modified Live Virus Vaccine
Recombinant Vaccine

Healthcare By Route of Administration (USD Billion, 2025-2035)

Intramuscular Injection
Intradermal Injection
Subcutaneous Injection

Healthcare By Immunoglobulins (USD Billion, 2025-2035)

Human Rabies Immunoglobulin (HRIG)
Equine Rabies Immunoglobulin (ERIG)

Healthcare By Application (USD Billion, 2025-2035)

Pre-Exposure Prophylaxis
Post-Exposure Prophylaxis

Healthcare By Dosage Form (USD Billion, 2025-2035)

Vials
Pre-Filled Syringes

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓